Prognostic value of treatment arm on survival end points
| . | Univariate analysis . | Adjusted for covariates . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| EFScens* | ||||||
| Arm B | .60 | .48-.75 | < .001 | .55 | .44-.69 | < .001 |
| Age | 1.01 | .99-1.02 | .42 | 1.01 | .99-1.02 | .39 |
| Female | .86 | .68-1.09 | .22 | .83 | .65-1.06 | .14 |
| WHO performance | 1.31 | 1.12-1.53 | .001 | 1.19 | 1.01-1.41 | .04 |
| S&D stage 3 | 1.41 | 1.06-1.88 | .02 | 1.21 | .90-1.64 | .21 |
| IgA | 1.20 | .92-1.57 | .17 | 1.28 | .90-1.80 | .17 |
| IgG | .91 | .73-1.14 | .42 | 1.04 | .77-1.39 | .80 |
| LDH > ULN | 1.81 | 1.38-2.38 | < .001 | 1.72 | 1.29-2.30 | < .001 |
| Log (β2m) | 1.31 | 1.11-1.54 | .001 | n.i. | — | — |
| Albumin | .98 | .96-1.00 | .02 | n.i. | — | — |
| ISS | 1.35 | 1.17-1.55 | < .001 | 1.27 | 1.09-1.48 | .002 |
| PFS | ||||||
| Arm B | .67 | .55-.82 | < .001 | .62 | .50-.76 | < .001 |
| Age | 1.02 | 1.00-1.03 | .04 | 1.02 | 1.00-1.03 | .02 |
| Female | .85 | .69-1.05 | .14 | .82 | .66-1.02 | .07 |
| WHO performance | 1.26 | 1.10-1.46 | .001 | 1.17 | 1.00-1.35 | .04 |
| S&D stage 3 | 1.33 | 1.03-1.72 | .03 | 1.18 | .90-1.55 | .22 |
| IgA | 1.28 | 1.01-1.63 | .04 | 1.37 | 1.00-1.87 | .05 |
| IgG | .90 | .73-1.10 | .32 | 1.06 | .80-1.39 | .68 |
| LDH > ULN | 1.83 | 1.42-2.36 | < .001 | 1.71 | 1.31-2.24 | < .001 |
| Log (β2m) | 1.28 | 1.09-1.49 | .002 | n.i. | — | — |
| Albumin | .98 | .97-1.00 | .02 | n.i. | — | — |
| ISS | 1.29 | 1.13-1.46 | < .001 | 1.23 | 1.07-1.41 | .003 |
| OS | ||||||
| Arm B | .96 | .74-1.25 | .77 | .92 | .71-1.20 | .54 |
| Age | 1.01 | .99-1.03 | .32 | 1.01 | .99-1.03 | .30 |
| Female | .87 | .66-1.14 | .31 | .90 | .68-1.20 | .48 |
| WHO performance | 1.27 | 1.06-1.52 | .009 | 1.16 | .96-1.40 | .13 |
| S&D stage 3 | 1.46 | 1.03-2.08 | .04 | 1.22 | .84-1.76 | .30 |
| IgA | 1.20 | .88-1.64 | .25 | 1.33 | .89-2.01 | .17 |
| IgG | .95 | .73-1.24 | .71 | 1.16 | .81-1.65 | .41 |
| LDH > ULN | 2.09 | 1.54-2.84 | < .001 | 1.83 | 1.33-2.51 | < .001 |
| Log (β2m) | 1.53 | 1.26-1.86 | < .001 | n.i. | — | — |
| Albumin | .97 | .96-.99 | .007 | n.i. | — | — |
| ISS | 1.43 | 1.21-1.69 | < .001 | 1.33 | 1.11-1.60 | .002 |
| . | Univariate analysis . | Adjusted for covariates . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| EFScens* | ||||||
| Arm B | .60 | .48-.75 | < .001 | .55 | .44-.69 | < .001 |
| Age | 1.01 | .99-1.02 | .42 | 1.01 | .99-1.02 | .39 |
| Female | .86 | .68-1.09 | .22 | .83 | .65-1.06 | .14 |
| WHO performance | 1.31 | 1.12-1.53 | .001 | 1.19 | 1.01-1.41 | .04 |
| S&D stage 3 | 1.41 | 1.06-1.88 | .02 | 1.21 | .90-1.64 | .21 |
| IgA | 1.20 | .92-1.57 | .17 | 1.28 | .90-1.80 | .17 |
| IgG | .91 | .73-1.14 | .42 | 1.04 | .77-1.39 | .80 |
| LDH > ULN | 1.81 | 1.38-2.38 | < .001 | 1.72 | 1.29-2.30 | < .001 |
| Log (β2m) | 1.31 | 1.11-1.54 | .001 | n.i. | — | — |
| Albumin | .98 | .96-1.00 | .02 | n.i. | — | — |
| ISS | 1.35 | 1.17-1.55 | < .001 | 1.27 | 1.09-1.48 | .002 |
| PFS | ||||||
| Arm B | .67 | .55-.82 | < .001 | .62 | .50-.76 | < .001 |
| Age | 1.02 | 1.00-1.03 | .04 | 1.02 | 1.00-1.03 | .02 |
| Female | .85 | .69-1.05 | .14 | .82 | .66-1.02 | .07 |
| WHO performance | 1.26 | 1.10-1.46 | .001 | 1.17 | 1.00-1.35 | .04 |
| S&D stage 3 | 1.33 | 1.03-1.72 | .03 | 1.18 | .90-1.55 | .22 |
| IgA | 1.28 | 1.01-1.63 | .04 | 1.37 | 1.00-1.87 | .05 |
| IgG | .90 | .73-1.10 | .32 | 1.06 | .80-1.39 | .68 |
| LDH > ULN | 1.83 | 1.42-2.36 | < .001 | 1.71 | 1.31-2.24 | < .001 |
| Log (β2m) | 1.28 | 1.09-1.49 | .002 | n.i. | — | — |
| Albumin | .98 | .97-1.00 | .02 | n.i. | — | — |
| ISS | 1.29 | 1.13-1.46 | < .001 | 1.23 | 1.07-1.41 | .003 |
| OS | ||||||
| Arm B | .96 | .74-1.25 | .77 | .92 | .71-1.20 | .54 |
| Age | 1.01 | .99-1.03 | .32 | 1.01 | .99-1.03 | .30 |
| Female | .87 | .66-1.14 | .31 | .90 | .68-1.20 | .48 |
| WHO performance | 1.27 | 1.06-1.52 | .009 | 1.16 | .96-1.40 | .13 |
| S&D stage 3 | 1.46 | 1.03-2.08 | .04 | 1.22 | .84-1.76 | .30 |
| IgA | 1.20 | .88-1.64 | .25 | 1.33 | .89-2.01 | .17 |
| IgG | .95 | .73-1.24 | .71 | 1.16 | .81-1.65 | .41 |
| LDH > ULN | 2.09 | 1.54-2.84 | < .001 | 1.83 | 1.33-2.51 | < .001 |
| Log (β2m) | 1.53 | 1.26-1.86 | < .001 | n.i. | — | — |
| Albumin | .97 | .96-.99 | .007 | n.i. | — | — |
| ISS | 1.43 | 1.21-1.69 | < .001 | 1.33 | 1.11-1.60 | .002 |
EFS indicates event-free survival; PFS, progression-free survival; OS, overall survival; WHO, World Health Organization; S&D, Salmon and Durie; ISS, International Scoring System; LDH, lactate dehydrogenase; ULN, upper limit of normal; β2m, β2-microglobulin; and n.i., not included in multivariate analysis (already used for ISS).
The subscript “cens” indicates that patients are censored at allo-SCT.